The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Clover Health Investments Corp’s stock clocked out at $2.51, down -0.79% from its previous closing price of $2.53. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 2.95 million shares were traded. CLOV stock price reached its highest trading level at $2.55 during the session, while it also had its lowest trading level at $2.495.
Ratios:
To gain a deeper understanding of CLOV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6. On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4. Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 18 ’25 when Reynoso Jamie L. sold 4,913 shares for $2.61 per share. The transaction valued at 12,823 led to the insider holds 2,767,240 shares of the business.
JAMIE REYNOSO bought 4,913 shares of CLOV for $12,774 on Dec 18 ’25. On Nov 04 ’25, another insider, Reynoso Jamie L., who serves as the CEO, Medicare Advantage of the company, sold 30,385 shares for $3.58 each. As a result, the insider received 108,778 and left with 2,793,411 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1296861952 and an Enterprise Value of 1094021888. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 3.56. Its current Enterprise Value per Revenue stands at 0.617 whereas that against EBITDA is -19.519.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.13, which has changed by -0.21316612 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is -9.33%, while the 200-Day Moving Average is calculated to be -16.65%.
Shares Statistics:
It appears that CLOV traded 8.49M shares on average per day over the past three months and 3795220 shares per day over the past ten days. A total of 391.56M shares are outstanding, with a floating share count of 391.44M. Insiders hold about 24.24% of the company’s shares, while institutions hold 26.45% stake in the company. Shares short for CLOV as of 1765756800 were 39929930 with a Short Ratio of 4.70, compared to 1763078400 on 43475437. Therefore, it implies a Short% of Shares Outstanding of 39929930 and a Short% of Float of 9.67.
Earnings Estimates
A detailed examination of Clover Health Investments Corp (CLOV) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.07, with high estimates of $0.07 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.04 and $0.04 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.06, with 1.0 analysts recommending between $0.06 and $0.06.
Revenue Estimates
In. The current quarter, 3 analysts expect revenue to total $467.06M. It ranges from a high estimate of $473.97M to a low estimate of $454.7M. As of. The current estimate, Clover Health Investments Corp’s year-ago sales were $336.96MFor the next quarter, 3 analysts are estimating revenue of $650.52M. There is a high estimate of $669.9M for the next quarter, whereas the lowest estimate is $635.46M.
A total of 3 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.91B, while the lowest revenue estimate was $1.89B, resulting in an average revenue estimate of $1.9B. In the same quarter a year ago, actual revenue was $1.37BBased on 3 analysts’ estimates, the company’s revenue will be $2.62B in the next fiscal year. The high estimate is $2.72B and the low estimate is $2.52B.
